Table 1 Comparison of clinical and radiological characteristics between patients with HER2 (−) and HER2 (+) EC.

From: Preoperative prediction of the HER2 status and prognosis of patients with endometrial cancer using multiparametric MRI-based radiomics: a multicenter study

Characteristic

Training cohort

(n = 215)

P value

Internal validation cohort (n = 92)

P value

External validation cohort 1 (n = 64)

P value

External validation cohort 2 (n = 121)

P value

HER2 (−)

(n = 126)

HER2 (+)

(n = 89)

HER2 (−)

(n = 54)

HER2 (+)

(n = 38)

 

HER2 (−)

(n = 41)

HER2 (+)

(n = 23)

HER2 (−)

(n = 67)

HER2 (+)

(n = 54)

Age, years

  

0.188

  

0.728

  

0.282

  

0.059

  < 60

90 (71.4)

56 (62.9)

 

36 (66.7)

24 (63.2)

 

27 (65.9)

12 (52.2)

 

46 (68.7)

28 (51.9)

 

  ≥ 60

36 (28.6)

33 (37.1)

 

18 (33.3)

14 (36.8)

 

14 (34.1)

11 (47.8)

 

21 (31.3)

26 (48.1)

 

Menopause status

  

0.724

  

0.418

  

0.885

  

0.570

Postmenopausal

72 (57.1)

53 (59.6)

 

33 (61.1)

20 (52.6)

 

26 (63.4)

15 (65.2)

 

35 (52.2)

31 (57.4)

 

Premenopausal

54 (42.9)

36 (40.4)

 

21 (38.9)

18 (47.4)

 

15 (36.6)

8 (34.8)

 

32 (47.8)

23 (42.6)

 

BMI, kg/m2

25.62 ± 3.20

25.30 ± 3.62

0.502

26.54 ± 2.55

25.75 ± 3.09

0.186

25.55 ± 3.06

24.89 ± 3.33

0.428

25.94 ± 2.94

25.69 ± 3.15

0.659

Differentiation

  

 < 0.001

  

0.030

  

0.026

  

 < 0.001

Poor

17 (13.5)

33 (37.1)

 

6 (11.1)

11 (28.9)

 

7 (17.1)

9 (39.1)

 

2 (3.0)

17 (31.5)

 

Moderate/Well

109 (86.5)

56 (62.9)

 

48 (88.9)

27 (71.1)

 

34 (82.9)

14 (60.9)

 

65 (97.0)

37 (68.5)

 

FIGO stage

  

0.152

  

0.702

  

0.516

  

0.194

I–II

112 (88.9)

73 (82.0)

 

47 (87.0)

32 (84.2)

 

31 (75.6)

19 (82.6)

 

62 (92.5)

46 (85.2)

 

III–IV

14 (11.1)

16 (18.0)

 

7 (13.0)

6 (15.8)

 

10 (24.4)

4 (17.4)

 

5 (7.5)

8 (14.8)

 

Tumor size, cm

  

0.334

  

0.099

  

0.759

  

0.828

 < 2

20 (15.9)

10 (11.2)

 

13 (24.1)

4 (10.5)

 

3 (7.3)

3 (13.0)

 

9 (13.4)

8 (14.8)

 

 ≥ 2

106 (84.1)

79 (88.8)

 

41 (75.9)

34 (89.5)

 

38 (92.7)

20 (87.0)

 

58 (86.6)

46 (85.2)

 

Tumor margin

  

0.410

  

0.202

  

0.773

  

0.971

Well-defined

106 (84.1)

71 (79.8)

 

50 (92.6)

31 (81.6)

 

37 (90.2)

22 (95.7)

 

56 (83.6)

45 (83.3)

 

Ill-defined

20 (15.9)

18 (20.2)

 

4 (7.4)

7 (18.4)

 

4 (9.8)

1 (4.3)

 

11 (16.4)

9 (16.7)

 

Tumor component

  

0.225

  

0.191

  

0.578

  

0.159

Solid

55 (43.7)

32 (36.0)

 

28 (51.9)

13 (34.2)

 

17 (41.5)

7 (30.4)

 

42 (62.7)

25 (46.3)

 

Solid-cystic

42 (33.3)

40 (44.9)

 

19 (35.2)

16 (42.1)

 

16 (39.0)

12 (52.2)

 

20 (29.8)

21 (38.9)

 

Cystic

29 (23.0)

17 (19.1)

 

7 (12.9)

9 (23.7)

 

8 (19.5)

4 (17.4)

 

5 (7.5)

8 (14.8)

 

Myometrial invasion

  

 < 0.001

  

0.018

  

0.041

  

0.029

Deep

21 (16.7)

41 (46.1)

 

14 (25.9)

19 (50.0)

 

8 (19.5)

10 (43.5)

 

15 (22.4)

32 (40.7)

 

Superficial

105 (83.3)

48 (53.9)

 

40 (74.1)

19 (50.0)

 

33 (80.5)

13 (56.5)

 

52 (77.6)

32 (59.3)

 

Lymph node status

  

0.034

  

0.137

  

0.842

  

0.072

Positive

18 (14.3)

23 (25.8)

 

11 (20.4)

13 (34.2)

 

5 (12.2)

4 (17.4)

 

6 (8.9)

11 (20.4)

 

Negative

108 (85.7)

66 (74.2)

 

43 (79.6)

25 (65.8)

 

36 (87.8)

19 (82.6)

 

61 (91.1)

43 (79.6)

 

Ascites

  

0.374

  

0.893

  

0.510

  

0.732

Present

30 (23.8)

26 (29.2)

 

12 (22.2)

8 (21.1)

 

8 (19.5)

3 (13.0)

 

12 (17.9)

11 (20.4)

 

Absent

96 (76.2)

63 (70.8)

 

42 (77.8)

30 (78.9)

 

33 (80.5)

20 (87.0)

 

55 (82.1)

43 (79.6)

 
  1. Abbreviations: BMI, body mass index; EC, endometrial cancer; FIGO, international federation of gynecology and obstetric; HER2, human epidermal growth factor receptor2.
  2. Bold indicates statistical significance at P<0.05 (two-tailed).
Back to article page